Joseph B. Conahan


Conahan, Joseph B.
Joseph Conahan's practice focuses on the representation of buyers, sellers and boards of directors in mergers, acquisitions, divestitures, joint ventures and other strategic transactions in the technology, life sciences, FinTech and financial services industries, as well as on counseling public companies on complex governance and disclosure matters.

Recent Highlights

Mr. Conahan recently has advised:

  • Analog Devices in its acquisition of the assets of Sand9;
  • Thermo Fisher Scientific in its acquisition of Advanced Scientifics;
  • Durata Therapeutics in its sale to Actavis plc;
  • Cynosure in the acquisition of the assets of Ellman International;
  • Kolltan Pharmaceuticals in its acquisition of Xetrios;
  • Analog Devices in its acquisition of Hittite Microwave;
  • Bottomline Technologies in its acquisition of Andera;
  • Thermo Fisher Scientific in the sale of its cell culture, gene modulation and magnetic beads businesses to GE Healthcare;
  • Analog Devices in the sale of its MEMS microphone business to InvenSense;
  • The Medicines Company in its acquisition of Recothrom from Bristol-Myers Squibb Company;
  • Dean Foods Company in the initial public offering and subsequent spin-off of its former subsidiary The WhiteWave Foods Company;
  • BAE Systems Safety Products in its sale to Takata Corporation;
  • Levitronix in the sale of its medical device business to Thoratec Corporation;
  • Constant Contact in its acquisition of the assets of Bantam Networks;
  • TARGUSinfo in its sale to Neustar;
  • Constant Contact in its acquisition of NutShell Mail;
  • Starent Networks in its sale to Cisco Systems; and
  • LTX in its business combination with Credence Systems.

Honors & Awards

  • Recipient of M&A Advisor's Sixth Annual 40 Under 40 Emerging Leaders Award

Community Involvement

Mr. Conahan's pro bono work includes the representation of organizations such as Bridge Boston Charter School, GlobalGiving Foundation and Boston Children's Chorus on a variety of matters.

Publications & News


January 13, 2016

Strong signs for New England M&A in 1H116

Partner Joseph Conahan offers insight into the 2016 M&A outlook in this Deal Drivers piece published by on January 13, 2016.

December 21, 2015

The Medicines Company Agrees to Divest its Hemostasis Portfolio to Mallinckrodt plc

On December 18, The Medicines Company (NASDAQ:MDCO) announced that it entered into a purchase agreement pursuant to which certain subsidiaries of Mallinckrodt plc will acquire The Medicines Company’s global portfolio of three hemostasis products – RECOTHROM® Thrombin topical (Recombinant), PreveLeak™, and RAPLIXA™ (fibrin sealant) – for a total potential consideration of up to $410 million.

June 25, 2015

Joseph Conahan Honored Among M&A Advisor's 40 Under 40

Partner Joseph Conahan has been named to M&A Advisor's Sixth Annual 40 Under 40 Emerging Leaders Awards, a global recognition honoring leading dealmakers, legal advisors and others in the mergers and acquisitions, financing and turnaround markets.

March 27, 2015

2015 M&A Report

Our 2015 M&A Report contains a detailed review of, and outlook for, the global M&A market. Other highlights include a comparison of deal terms in public and private acquisitions, updates on takeover defenses and the current climate around proxy access, and a look at the use of social media by public companies and activist shareholders in contested situations.

March 19, 2015

WilmerHale Attorneys to Participate in 2015 ABA Business Law Section Spring Meeting

Several WilmerHale attorneys will speak at the 2015 ABA Business Law Section Spring Meeting, taking place April 16–18 at the San Francisco Marriot Marquis and InterContinental San Francisco in San Francisco, CA.

February 5, 2015

Thermo Fisher Scientific Strengthens Bioproduction Offering by Acquiring Advanced Scientifics, Inc.

Thermo Fisher Scientific Inc., the world leader in serving science, today announced it has acquired Advanced Scientifics, Inc. (ASI).

October 8, 2014

Actavis to Acquire Durata Therapeutics, Inc.

On October 6, 2014, WilmerHale client Durata Therapeutics announced that it had entered into a definitive merger agreement with Actavis plc under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock.

June 9, 2014

WilmerHale Representing Analog Devices in Pending Acquisition of Hittite Microwave Corporation

WilmerHale is representing its longtime client Analog Devices, Inc., a global leader in high-performance semiconductors for signal processing applications, in its proposed acquisition of Hittite Microwave Corporation.

January 7, 2014

WilmerHale Represents Thermo Fisher Scientific in Transaction with GE Healthcare

Thermo Fisher has agreed to sell its cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare for approximately $1.06 billion.

January 6, 2014

WilmerHale Announces the Elevation of Partners and Special Counsel

We are pleased to announce the elevation of our new partners and special counsel.


Skip Navigation Links.


JD, magna cum laude, Georgetown University Law Center, 2004, Order of the Coif, Articles and Notes Editor, American Criminal Law Review

BS, cum laude, Georgetown University, 2001

Bar Admissions


District of Columbia